Genitourinary Cancer News

The FDA approved pembrolizumab in combination with axitinib for first-line treatment of advanced renal cell carcinoma.

A novel urine test may detect bladder cancer earlier than available methods, according to study results published in Cancer Discovery.

A preclinical study that yielded new insights into a rare pediatric malignancy laid the foundation for a phase 2 trial that is evaluating a novel treatment approach in a specific type of kidney cancer.

The FDA today granted accelerated approval to erdafitinib for the treatment of adults with locally advanced or metastatic bladder cancer that progressed during or following platinum-containing chemotherapy.

The FDA granted priority review to pembrolizumab, an anti-PD-1 therapy, for three oncology indications.

FORT WORTH, Texas — Patients with advanced renal cell carcinoma may be able to receive a lower starting dose of cabozantinib without compromising efficacy, according to study results presented at HOPA Ahead 2019.

FORT WORTH, Texas — An evaluation of physician prescribing practices showed utilization of corticosteroids for management of immune-mediated adverse events among patients with cancer who received immune checkpoint inhibitors often was not based on national guidelines, according to study results presented at HOPA Ahead 2019.

Antoni Ribas, MD, PhD, has been elected president-elect of American Association for Cancer Research for the 2019-2020 term.

NEW YORK — First-line treatment of patients with metastatic renal cell carcinoma has evolved considerably in the past 18 months with FDA approval of cabozantinib monotherapy and the combination of ipilimumab and nivolumab.

Click here to read the Cover Story, “Targeted treatments for acute myeloid leukemia yield modest improvements, great hope.”